Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13
ESTIMATED NET ASSET VALUE AT
· Estimated NAV at
· Excluding new investments, 99.5% by value of portfolio dated
· PPET paid
· PPET completed one new primary fund commitment, one direct investment, and one secondary transaction during the month
· Outstanding commitments of
· Short term resources (cash balances and undrawn credit facilities) were £295.0 million at
Estimated NAV
At
Performance
PPET's total return and comparator reference performance as at
|
Performance over the last |
6 months |
1 year |
3 years |
5 years |
10 years |
Since Inception |
|
NAV Total Return[2] |
4.9% |
7.6% |
15.6% |
81.3% |
270.3% |
1112.7% |
|
Share Price Total Return[3] |
1.0% |
7.0% |
49.3% |
103.5% |
266.7% |
831.2% |
|
FTSE All-Share Index[4] |
11.6% |
16.2% |
50.0% |
84.1% |
118.3% |
322.2% |
|
|
|
|
|
|
|
|
|
Performance in the 12 months to |
|
|
|
|
|
|
|
NAV Total Return2 |
|
7.6% |
0.8% |
5.1% |
21.6% |
37.9% |
|
Share Price Total Return3 |
|
7.0% |
24.9% |
11.7% |
-15.1% |
60.6% |
|
FTSE All-Share Index4 |
|
16.2% |
13.4% |
13.8% |
-4.0% |
27.9% |
Investment activity
In September, the Company made a
During the month, PPET signed an agreement to acquire a portfolio of fourteen fund investments and one direct investment in a secondary transaction, with a total consideration of
A
Portfolio cashflows
PPET paid
Notable primary fund drawdowns during the month included:
· Archimed - Platform 2: to fund an investment in ZimVie, a US- headquartered business that develops, manufactures, and distributes regenerative biomaterials and implants for the dental industry, and to partially repay the subscription line facility used for the fund's investment in Ceva in
· IK Partnership Fund III: to fund a new investment into Octime, a French software developer specialising in workforce management software.
PPET received
Notable realisations during the month included:
· Triton Fund V: proceeds from the continued sell down of listed shares in RENK, a German manufacturer of drivetrain technology, following the business's IPO in 2023.
· Vitruvian I CF: partial exit of Benify, a HR technology company providing a benefit and rewards platform.
Commitments
The Company had
Credit facility and cash balances
The Company has a
During September, the Company drew
In addition, the Company had cash balances of
Share Buybacks
Pursuant to the Company's share buyback programme, the Company bought back 117,000 ordinary shares into treasury during September. The positive impact of these buybacks is reflected in the movement in NAV for the month.
Correction relating to the
In the Company's previous announcement of the Estimated NAV at
For further information please contact:
|
|
|
|
|
|
|
|
|
|
|
+44 (0)20 7597 4000 |
|
|
|
|
|
|
|
|
|
|
SEC Newgate |
+44 (0)20 3757 6872 |
|
|
Notes:-
Additional detail about PPET's NAV and investment diversification can be found on PPET's website (www.patriaprivateequitytrust.com). Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website is incorporated into, or forms part of, this announcement.
[1] PPET's valuation policy for private equity funds and direct investments is based on the latest valuations reported by the underlying managers. For the Company's valuation at
This is an update from the estimated NAV at
[2] NAV Total Return assumes reinvesting any dividends in the NAV of the Company on the date on which that dividend goes ex-dividend and assumes monthly compounding.
[3] Share Price Total Return assumes reinvesting any dividends in the share price of the Company on the date on which that dividend goes ex-dividend. Source: London Stock Exchange Group Workspace
[4] Comparator Index - The Company is not managed with direct reference to any index or its constituents. Source: London Stock Exchange Group Workspace
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the